Article Text

Download PDFPDF
Case report
Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma
  1. Tiffany Foo1,
  2. Gonzalo Tapia Rico1,2 and
  3. Michael P Brown1,2
  1. 1Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
  2. 2School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
  1. Correspondence to Dr Gonzalo Tapia Rico; gonzalo.tapiarico{at}


Despite the increasing incidence of metastatic melanoma in the older population, there are relatively limited data for those older than 75 years of age. Elderly patients are often under-represented in clinical trials. In addition, elderly patients in trials often have a lower Eastern Cooperative Oncology Group score and fewer comorbidities and may thus not truly reflect the realities of day-to-day clinical practice. We present a case of a 95-year-old woman who had extensive and unresectable subcutaneous and dermal deposits of metastatic melanoma of her right leg, which caused oedema and reduced mobility. She was treated concurrently with pembrolizumab and radiotherapy to her leg lesions of melanoma. She has had an excellent response to treatment, with complete resolution of the subcutaneous and dermal metastatic deposits and has not developed any immune-related toxicities. Our experience demonstrates that anti-programmed-death-receptor-1 therapy can be given safely and effectively even in very elderly metastatic melanoma patients.

  • medical management
  • skin cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors TF and GTR did the literature search. GTR provided the medical information for this case report and gained consent from the patient. TF wrote the first draft of the manuscript. GTR and MPB revised it critically for important intellectual content. All authors read and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MPB’s institution has received honoraria for his attendance at melanoma advisory boards held by Merck, Sharp and Dohme.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.